QLT Share Price

Open 2.69 Change Price %
High 2.70 1 Day -0.05 -1.89
Low 2.31 1 Week 0.00 0.00
Close 2.59 1 Month 0.29 12.61
Volume 5150 1 Year -1.10 -29.81
52 Week High 3.88
52 Week Low 1.60
QLT Important Levels
Resistance 2 2.95
Resistance 1 2.80
Pivot 2.53
Support 1 2.38
Support 2 2.23
TSE Canada Most Active Stocks
BIN 41.40 -1.62%
BIN 41.40 -1.62%
LSG 2.08 8.33%
LSG 2.08 8.33%
LSG 2.08 8.33%
TBE 0.03 0.00%
SC 60.83 -0.44%
PRE 0.64 0.00%
PRE 0.64 0.00%
PRE 0.64 0.00%
More..
TSE Canada Top Gainers Stocks
CUR 0.02 100.00%
CUR 0.02 100.00%
CUR 0.02 100.00%
TVI 0.02 100.00%
RN 0.11 22.22%
RN 0.11 22.22%
PWC 0.12 20.00%
PWC 0.12 20.00%
IMP 0.07 16.67%
IMP 0.07 16.67%
More..
TSE Canada Top Losers Stocks
GBV 0.46 -24.59%
AVP 0.07 -12.50%
AVP 0.07 -12.50%
AVP 0.07 -12.50%
AVP 0.07 -12.50%
NKO 0.08 -11.11%
NKO 0.08 -11.11%
NKO 0.08 -11.11%
TBL 0.95 -7.77%
BAA 0.24 -7.69%
More..

QLT Inc (TSE: QLT)

QLT Technical Analysis 3
As on 30th Nov 2016 QLT Share Price closed @ 2.59 and we RECOMMEND Buy for LONG-TERM with Stoploss of 2.46 & Buy for SHORT-TERM with Stoploss of 2.42 we also expect STOCK to react on Following IMPORTANT LEVELS.
QLT Target for December
1st Target up-side 3.07
2nd Target up-side 3.41
3rd Target up-side 3.74
1st Target down-side 2.11
2nd Target down-side 1.77
3rd Target down-side 1.44
QLT Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.qltinc.com
QLT Address
QLT
887 Great Northern Way
Suite 101
Vancouver, BC V5T 4T5
Canada
Phone: 604-707-7000
Fax: 604-707-7001
Interactive Technical Analysis Chart QLT Inc ( QLT TSE Canada )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on QLT Inc
QLT Business Profile
QLT Inc., a biotechnology company, develops and commercializes ocular products that address the unmet medical needs of patients and clinicians worldwide. It focuses on the development of QLT091001, a synthetic retinoid compound, which is in phase Ib retreatment clinical trials for the treatment of leber congenital amaurosis and retinitis pigmentosa; phase Ib clinical trials for the treatment of Retinitis Pigmentosa with autosomal dominant mutation in RPE65; and phase IIa clinical trials for the treatment of impaired dark adaptation. The company was founded in 1981 and is headquartered in Vancouver, Canada.